To facilitate preclinical in vivo PD/PK and toxicological studies as well as in vivo efficacy evaluation of potential cancer immunotherapies, Creative Biolabs has established over 200 validated and well-characterized CDX models as well as luciferase-labeled CDX models for your choice. Our broad range of cell lines ensure a large variety of research options for your candidates.
| Type | Tumor Cell Line |
| Adrenal | H295R |
| ■ Brain Cancer | LN-229, SF-295, SK-N-AS, U87 MG, U251 |
| ■ Breast Cancer | 2LMP, 4T1, Bcap-37, BT20, BT474, DU4475, EMT6, HCC-70, HCC-1806, HCC-1954, JIMT-1, KPL-4, MCF-7, MCF-7-luc, MDA-MB-157, MDA-MB-231, MDA-MB-231-luc, MDA-MB-453, MDA-MB-468, MDA-N, Mx-1, SKBr-3, SUM159, T47D, ZR-75-1, ZR-75-30 |
| ■ Bladder Cancer | BFTC905, HT-1197, HT-1376, J82, RT4, SCaBER, SW780, 5637, T24, UM-UC3 |
| ■ Bone Cancer | U-2 OS |
| ■ Cervical Carcinoma | AN3 CA, ECC-1, HEC-1-A, ME-180, MFE-280, Hela, Hela-luc, KB-3-1 |
| ■ Colorectal Cancer | CL-34, Colon137, COLO 201, COLO 205, COLO 320 DM, CT-26, CW-2, DLD-1, HCT-15, HCT-8, HT-29, HT-29-luc, HCT 116, HCT116 P53 K0(-/-), KM12, LoVo, LS-174T, LS-180, LS411N, LS1034, NCI-H716, RKO, SW48, SW403, SW480, SW620, SW837, WiDr |
| ■ Endometrium Cancer | HEC-1B |
| ■ Epidermoid Carcinoma | A-431 |
| ■ Gallbladder Carcinoma | Mz-ChA-1, Mz-ChA-2, Wittier |
| ■ Gastric Carcinoma | AGS, AGS-luc, BGC-823, HGC-27, Hs746T, MGC-803, MKN-1, MKN-28, MKN-45, MKN-45-luc, NCI-N87, NUGC-4, NUGC-4-luc, SCH, SGC-7901, SNU-5, SNU-16, SNU-16-luc, Hs 746T |
| ■ Glioma | LN-229, U-87 MG, U-87 MG-luc, U-373, U-343 |
| ■ Head and neck Cancer | CRL-1624, FaDu, KB |
| ■ Liver Cancer | Bel-7402, HCCLM3, HCCLM3-luc, Hep3B2.1-7, Hep3B, Hep3B-luc, HepG 2, HepG 2-luc, HuH-7, PLC/PRF/5, SNU-398, QGY-7703, SK-HEP-1, SMMC-7721 |
| ■ Lung Cancer | 95-D, A-427, A549, A549-luc, Calu-1, Calu-3, Calu-6, COR-L23, DMS114, H23, H69, H82, H211, H510, H526, H1299, H1975, H226, H292, H2171, H358, H441, H460, H520, H522, H647, H727, H810, H1581, H1650, H1792, H1993, H2009, H2030, H2228, H358, HCC-15, HCC-44, HCC-827, KLN205, LL/2, LLC1, MSTO-211H, NCl-H69, NCl-H146, NCl-H209, NCI-H226, NCI-H446, NCI-H460, NCI-H466, NCI-H520, NCI-H522, NCI-H526, NCl-H720, NCl-H1155, NCI-H1688, NCl-H1770, NCI-H1781, NCI-H1975, NCI-H1963, NCI-H1975-luc, NCl-H2106, NCI-H2122, NCI-H2126, NCI-H2228, PC-10, QG-56, SHP-77, SK-MES-1, SW1573 |
| ■ Melanoma | A2058, A375, A375-luc, B16, C32, CHL-1, COLO 800, HMCB, IGR-1, IGR-37, M-13, MDA-MB-435s, MeWo, SK-MEL-5, SK-MEL-30, UACC-62, WM98-1 |
| ■ Mesothelioma | MSTO-211H |
| ■ Nasopharyngeal Carcinoma | S18, S26 |
| ■ Neuroblastoma | IMR5-75, Kelly, SK-N-MC, SK-N-SH, SKNAS |
| ■ Ovarian Cancer | A2780, A2780l-luc, ES-2, HOC-22, HO-8910PM, PA-1, IGR0V1, OV-90, OVCAR-3, OVCAR-5, OVCAR-8/ADR, SK-OV-3, TOV-21G |
| ■ Pancreatic Cancer | AsPC-1, BxPc-3, BxPc-3-luc, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF II, Hup-T3, KP4, MIA, MIA-luc, MiaPaCa-2, PaCa-2, PaCa-2-luc, PANC-1, Patu-8902, PSN-1 |
| ■ Prostate Cancer | 22Rv.1, CL-1, DU 145, LNCaP clone FGC, PC3, PC-3M-luc, VCaP |
| ■ Renal Carcinoma | A498, ACHN, Caki-1, Caki-2, 786-O, 786-O-luc, G-401, G-402, OS-RC-2, RENCA |
| ■ Rhabdomyosarcoma | A-673 |
| ■ Sarcoma | HT-1080, MG-63, RD-ES, SJSA-1, S-180 |
| ■ Skin Cancer | Clone M3 |
| ■ Thyroid Cancer | 8505C, FTC-238, K1 |
| ■ Uterine | ECC-1, HEC-1-A, HEC-1-B, MFE-280 |
| ■ Vulva Cancer | A-431 |
| Type | Tumor Cell Line |
| ■ Acute Lymphoblastic Leukemia | KARPAS-299, MOLM-13, MOLT-4, NALM-6, Jurkat, E6-1, CCRF-CEM |
| ■ Acute Monocytic Leukemia | U937, THP-1, MV4-11, MV4-11-luc |
| ■ Acute Myeloid Leukemia | EOL-1, HL-60, KG-1, MV4-11 |
| ■ Acute Myeloblastic Leukemia | Kasumi-1, Kasumi-3(CD33+) |
| ■ Acute Promyelocytic Leukemia | HL-60 |
| ■ Chronic Myeloid Leukemia | K-562, K-562-luc |
| ■ Eosinophilic Leukemia | EOL-1 |
| ■ Erythro Leukemia | TF-1 |
| ■ Histiocytic Lymphoma | U-937 |
| ■ Megakaryoblastic Leukemia | SET-2 |
| ■ Multiple Myeloma | H929, KMS-11, KMS-26, KMS-12-BM, OPM-2, RPMI 8226, SK-MM-2, 8226-luc, ARH-77, ML-2 |
| ■ Non-Hodgkin Lymphoma | DoHH-2, Daudi, Farage, Granta 519, JEKO-1, KARPAS-299, Namalwa, Raji, Raji-luc, Ramos, REC-1, RL, SU-DHL-1, SU-DHL-4, WSU-DLCL2 |
| ■ Lymphoma (B-cell) | Mino, Namalwa |
With experienced scientists and substantial breadth of services, Creative Biolabs can assist in selecting the most appropriate CDX model to fit your candidates and cancer type. Customized CDX models are also available upon request. Please contact us for detailed information, and we are looking forward to working with you.
For Research Use Only | Not For Clinical Use
Download our brochure